The oral exposure challenge in PROTACs: Key aspects for early drug development
PROTACs, initially a promising concept, have now become a clinically validated modality. The U.S. FDA’s approval of vepdegestrant (Veppanu®) in May 2026 showed their potential across various disease areas. However, despite their intriguing options like event-driven, catalytic degradation, their development as oral medicines presents significant hurdles.
Oral Exposure Limitations
PROTACs’ large size, high polarity, and beyond-Rule-of-Five (bRo5) characteristics can hinder their solubility, permeability, and systemic exposure, making oral optimization a complex, cross-functional task. Traditional small-molecule rules, like Lipinski’s Rule of Five, do not fully predict oral exposure in the bRo5 chemical space.
Related: PharmSci 360 Adds Credibility and Post‑Animal Tracks
Recent research suggests that solvent-exposed hydrogen-bond donors (eHBD), conformational behavior, and polarity shielding are key factors in developing orally bioavailable PROTACs. A 2024 study identified an upper limit of approximately eHBD ≤2 as a useful guide within related oral PROTAC series.
Strategies for Enhancing Oral Exposure
Understanding where exposure is lost is key to improving it. Determining a PROTAC’s performance under fed-state conditions can help, as solubility in the gastrointestinal tract is vital for oral absorption. Biorelevant solubility testing and fit-for-purpose DMPK and bioanalytical studies can assess the impact of food on absorption and PK profile.
Linker optimization can enhance cellular permeability, making it vital in oral PROTAC development. Studies show that replacing a PEG linker with a 1,4-disubstituted phenyl ring and reducing unnecessary hydrogen-bonding features can improve membrane permeability. However, permeability gains should be balanced with degradation biology and early ADME profiling.
Enhancing metabolic stability is another key strategy for preserving systemic exposure. Linker design, length, attachment site, and conformational constraint can affect metabolic stability and complex formation. An integrated approach, combining lead optimization with mechanism-relevant assays and early ADME/DMPK studies, can improve exposure without compromising the degrader’s biology.
Related: Merck and Moderna Unveil Personalized Cancer Vaccine
E3 ligase selection also plays a key role in oral PROTAC development. CRBN-based degraders often support smaller designs, making them a better choice for oral optimization. However, intramolecular hydrogen bonds and prodrug strategies may be necessary to improve cell permeability and overcome exposure barriers.
In some cases, adjacent targeted protein degradation modalities like molecular glues can offer alternative strategies when oral exposure remains challenging. These simpler, structurally distinct compounds can create different formulation opportunities and provide a more favorable starting point for permeability and PK testing.
With clinical and regulatory validation, PROTACs have demonstrated their potential as powerful drugs. However, many will succeed or fail based on whether drug developers can address the oral-development challenges of solubility, permeability, metabolism, and exposure early enough for confident candidate selection and IND readiness.
